COR Cortex Pharmaceuticals,

NI Research today released the September issue of NeuroInvestment, featuring a review of Alzheimer's therapeutics. This review stands in sharp contrast with the common rehashing of press releases and corporate spin. The implications of recent clinical failures are discussed in terms of how they affect the primacy of the amyloidmodel. The review also discusses a challenge to the validity of the BACE target of concern to the many companies that have devoted resources to BACE inhibitors.

These developments require a recalibration of what constitutes a comprehensive AD pipeline, and opens the door for therapeutics utilizing other mechanisms of action, including those addressing tau, metal-binding, and neurotrophics.

Over 170 therapeutics programs from 110 companies are included in this review. They range from highly publicized projects like Elan/Wyeth's bapineuzumab, Lilly's amyloid antibody, Medivation'sDimebon, and Prana's PBT-2; to those whose star is now ascending, such as Allon Therapeutics and TauRx; to the still under-the-radar programs from such companies as Accera, American Life Sciences Partners, EnVivo Pharmaceuticals, Neuronascent, and Sanomune.

The September review examines the increased disregard for thorough Phase II testing in Alzheimer's, the seeds being sown for catastrophic Phase III failures like those already experienced by Myriad Genetics and Neurochem. It also includes a review of Allon Therapeutics (TSX: NPC); a look at Vanda's fading prospects; positive data for Titan Pharmaceuticals and Cortex Pharmaceuticals (AMEX: COR); and a comment on Catalyst Pharma's plan to develop vigabatrin for obesity.

NeuroInvestment is the independent, monthly review of the neurotherapeutics area. Its reputation has been built via thirteen years of objective, insightful, and critical coverage of the neurotherapeutics field. A one-year corporate subscription is $1600, email or hardcopy. Add $250 for dual delivery, add $50 for airmail delivery outside North America. A three month trial is US$600. The September issue is also being made available as a single purchase, US$400.

NI Research is the leading publisher of independent research on the neurotherapeutics industry. NI Research has published NeuroInvestment since 1995, the Private CNS Company Review since 2003, and CNS Disorders/Therapeutics since 2007. NI Research also provides inlicensing consultation and custom services. NI Research has developed an unmatched information base regarding both publicly and privately-held neuro-oriented companies.

Contact: NI Research P.O. Box 1028, Cardiff CA 92007 760.230.2581 Email Contact Website: www.niresearch.com